Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deli… Read more
Arecor Therapeutics PLC (AREC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.400x
Based on the latest financial reports, Arecor Therapeutics PLC (AREC) has a cash flow conversion efficiency ratio of -0.400x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.14 Million) by net assets (GBX2.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arecor Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Arecor Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Arecor Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arecor Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VTXGF
PINK:VTXGF
|
0.108x |
|
MER
WAR:MER
|
-0.031x |
|
Kelani Valley Plantations PLC
CM:KVALN0000
|
N/A |
|
Asiabest Group International Inc
PSE:ABG
|
-0.039x |
|
SUN
WAR:SUN
|
N/A |
|
Guardian Capital Partners PLC
CM:WAPON0000
|
N/A |
|
Challenger Energy Group PLC
LSE:CEG
|
-0.008x |
|
medondo holding AG
XETRA:AMI
|
-0.067x |
Annual Cash Flow Conversion Efficiency for Arecor Therapeutics PLC (2018–2024)
The table below shows the annual cash flow conversion efficiency of Arecor Therapeutics PLC from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX5.35 Million | GBX-9.15 Million | -1.712x | -179.16% |
| 2023-12-31 | GBX9.53 Million | GBX-5.84 Million | -0.613x | +0.73% |
| 2022-12-31 | GBX17.45 Million | GBX-10.78 Million | -0.618x | -110.20% |
| 2021-12-31 | GBX18.55 Million | GBX-5.45 Million | -0.294x | +87.75% |
| 2020-12-31 | GBX773.79K | GBX-1.86 Million | -2.399x | -1577.65% |
| 2019-12-31 | GBX3.21 Million | GBX-458.80K | -0.143x | +75.93% |
| 2019-05-31 | GBX4.22 Million | GBX-2.50 Million | -0.594x | +19.14% |
| 2018-05-31 | GBX670.33K | GBX-492.57K | -0.735x | -- |